Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

ENDRA Life Sciences (NDRA) Net Income towards Common Stockholders (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$3.1 million as the latest value for Q4 2021.

  • Quarterly Net Income towards Common Stockholders fell 37.94% to -$3.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$11.4 million through Dec 2021, up 6.34% year-over-year, with the annual reading at -$7.0 million for FY2025, 38.93% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2021 was -$3.1 million at ENDRA Life Sciences, down from -$2.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$741623.0 in Q1 2017, with the low at -$9.0 million in Q4 2019.
  • Average Net Income towards Common Stockholders over 5 years is -$2.8 million, with a median of -$2.7 million recorded in 2019.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 281.68% in 2019, then soared 75.07% in 2020.
  • Over 5 years, Net Income towards Common Stockholders stood at -$2.3 million in 2017, then dropped by 3.09% to -$2.4 million in 2018, then tumbled by 281.68% to -$9.0 million in 2019, then skyrocketed by 75.07% to -$2.3 million in 2020, then plummeted by 37.94% to -$3.1 million in 2021.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$3.1 million, -$2.7 million, and -$3.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.